SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology ($GSIT) is trending due to news highlighting their Compute-In-Memory APU achieving GPU-class AI performance with significantly lower energy costs, sparking community interest in its potential to compete with industry giants like NVDA. Discussions revolve around the APU's performance and energy efficiency, with some viewing GSIT as an overlooked player in the AI and drone sectors due to its exposure to high-speed memory solutions and defense contracts.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending after announcing plans to explore rare earth production at its U.S. mining sites, potentially making it a key player in America's push for critical mineral independence. The community is discussing the company's strategic shift from steel to strategic minerals, with some believing it's a smart move given China's tightening export controls, while others express skepticism and focus on debt reduction.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

REPL is experiencing a surge driven by news of the FDA accepting the resubmission of its Biologics License Application for RP1, a melanoma treatment. Community members are actively discussing price target upgrades and the potential for a short squeeze, while also weighing the possibility of future dilution. The stock's movement is also being compared to other trending tickers in the sector.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem ($VSTM) is trending due to positive data released by partner GenFleet Therapeutics regarding their lung cancer drug GFH375, showing promising response rates in NSCLC patients. The community is discussing the potential implications of these results, including a possible short squeeze, buyout scenarios, and comparing VSTM to competitors like RVMD. There is optimism regarding upcoming catalysts, such as presentations, NCCN decisions, and potential partnerships.

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.

RAPT Therapeutics Inc

RAPT Therapeutics is trending following the announcement of positive topline data from its Phase 2 trial of RPT904 in Chronic Spontaneous Urticaria, leading to discussions about potential price targets and the strength of the biotech momentum. However, some community members are expressing concerns about potential offerings and drops, while others remain optimistic about the company's future and potential breakouts. The stock is also being mentioned in connection with other trending stocks and potential squeeze opportunities.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix ($CRMD) is trending after reporting preliminary Q3 results and raising FY25 revenue guidance, leading to a surge in stock price. The community is actively discussing the company's profitability, potential for a short squeeze, and a possible acquisition by Pfizer. Positive real-world evidence and further catalysts are anticipated, while some investors express frustration with management decisions.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity (CELC) is trending following positive Phase 3 trial data for its breast cancer therapy, with the community actively discussing the potential for FDA approval and a possible buyout. The stock's significant pre-market surge has sparked conversations about its valuation and future prospects in the biotech sector. Community members are weighing the potential for continued gains against the possibility of a pullback.

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Corbus Pharmaceuticals Holdings Inc

CRBP is trending amid discussions of market manipulation and a significant drop from pre-market highs, despite recent analyst upgrades and price targets. The community is actively debating the impact of upcoming catalysts and data releases, particularly around CRB-701, while also noting the high institutional ownership and short interest. Overall, conversation is centered on the potential for a rebound following an overreaction to news in the broader sector, with some seeing it as a buying opportunity.

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Exelixis Inc

Exelixis is trending due to discussions around unusual options activity and potential bullish setups, including a possible short squeeze due to high short interest. Community members are also focused on the company's long-term potential, driven by its commercial product and pipeline updates, with some viewing it as a possible acquisition target. Recent analyst ratings and target price adjustments are contributing to the increased attention on the stock.

BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. It is also involved in the development of liquid biopsy tests for the early detection of biomarkers that are linked to diseases. It operates through the BioNexus Malaysia and Chemrex segments. The company was founded by Liew Choong-Chin on May 12, 2017 and is headquartered in Kuala Lumpur, Malaysia.

BioNexus Gene Lab Corp

BGLC is trending due to a recently announced strategic partnership term sheet, sparking excitement around potential growth. The community is actively discussing the company's low float and potential for a significant run, with some highlighting its past as a known runner. Community members also point to the company's Ethereum-focused treasury strategy as a potential catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The initiative to refocus on rare earths came alongside Q3 earnings, which met EPS estimates but missed on revenue.</li><li>CEO Lourenco Goncalves stated the firm saw the “renewed importance” of rare earths, which drove the company to re-focus on the “potential opportunity.”</li><li>He said Cleveland-Cliffs plans to leverage two U.S. sites, in Michigan and Minnesota, identified as having the strongest rare-earth potential.</li></ul>Cleveland-Cliffs’ (CLF) stock rose in pre-market trade on Monday,&nbsp;on track to hit more than a year high, and was among the top trending tickers on Stocktwits after its CEO, Lourenco Goncalves, stated the company could expand into rare-earths, a comment made alongside its third-quarter earnings release.CLF’s stock rose&nbsp;over 15% in pre-market trade,&nbsp;trading at levels not seen since&nbsp;July 2024,&nbsp;with retail sentiment on Stocktwits in ‘bullish’ territory. Chatter rose to ‘high’ from ‘normal’ levels over the past day.&nbsp;<h2 class="st-heading-2">Why Was Cleveland-Cliffs’ Stock Rising In Pre-Market Trade?</h2>The rally came despite the company reporting third-quarter (Q3) earnings largely in line with expectations. Cleveland-Cliffs posted a loss per share of $0.45, matching analyst forecasts, while revenue reached $4.7 million, slightly below the consensus estimate of $4.8 million, according to Koyfin data.The shares rallied on Goncalves stating that rare-earths could represent a strategic growth area for the company. "Beyond steelmaking, the renewed importance of rare earths has driven us to re-focus on this potential opportunity at our upstream mining assets," he said.&nbsp;<blockquote>"It is our obligation to do so as a company with our geological footprint. Two sites in Michigan and Minnesota show the most potential, with geological surveys indicating key rare-earth mineralization."&nbsp; – Lourenco Goncalves, CEO, Cleveland-Cliffs</blockquote>He highlighted the broader implications for manufacturing and national strategy, amid the trade tensions between the U.S. and China. "If successful, it would align Cleveland-Cliffs with the broader national strategy for critical material independence, similar to what we achieved in steel,” he said. “American manufacturing shouldn’t rely on China or any foreign nation for essential minerals, and Cliffs intends to be part of the solution.”The comments come as interest in rare earths has surged after China announced new export controls around rare earth elements, technologies, and sand processing equipment earlier this month.&nbsp;Shares of Cleveland-Cliffs have gained nearly 40% this year and around 2% in the last 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-price-tops-110000-as-crypto-market-rebounds/ch6CMKdR3Y1">Bitcoin Tops $110,000 As Crypto Market Rebounds On Trump’s Optimism Over China Trade Talks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cleveland-Cliffs Inc. Mining company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

CLF Stock Rises After Cleveland-Cliffs CEO Signals Shift Toward Rare-Earths

The initiative to refocus on rare earths came alongside Q3 earnings, which met EPS estimates but missed on revenue.

Equity

Cleveland-Cliffs (CLF) Reports Q3 Loss, Misses Revenue Estimates

Cleveland-Cliffs (CLF) delivered earnings and revenue surprises of +6.25% and -3.12%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Cleveland-Cliffs (CLF) Dips More Than Broader Market: What You Should Know

Cleveland-Cliffs (CLF) closed the most recent trading day at $13.56, moving 2.8% from the previous trading session.

Investors Heavily Search Cleveland-Cliffs Inc. (CLF): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Cleveland-Cliffs (CLF). This makes it worthwhile to examine what the stock has in store.

Curious about Cleveland-Cliffs (CLF) Q3 Performance? Explore Wall Street Estimates for Key Metrics

Besides Wall Street's top-and-bottom-line estimates for Cleveland-Cliffs (CLF), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.

Analysts Estimate Cleveland-Cliffs (CLF) to Report a Decline in Earnings: What to Look Out for

Cleveland-Cliffs (CLF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why the Market Dipped But Cleveland-Cliffs (CLF) Gained Today

In the most recent trading session, Cleveland-Cliffs (CLF) closed at $12.81, indicating a +1.34% shift from the previous trading day.

Here is What to Know Beyond Why Cleveland-Cliffs Inc. (CLF) is a Trending Stock

Cleveland-Cliffs (CLF) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Nucor & The Nuclear Company Team Up to Boost U.S. Supply Chain

NUE partners with The Nuclear Company to rebuild America's nuclear supply chain and strengthen U.S. energy infrastructure.

Cleveland-Cliffs (CLF) Stock Dips While Market Gains: Key Facts

Cleveland-Cliffs (CLF) closed at $12.2 in the latest trading session, marking a -4.98% move from the prior day.

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

CLF
Cleveland-Cliffs Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CLF News

CLFCleveland-Cliffs Inc